JUNS - jupiterneurosciences.com Debt to Book Capitalization Ratio

Graphic logo of Jupiter Neurosciences Inc (JUNS)

The current debt-to-book capitalization ratio allows for an assessment of the financial stability of Jupiter Neurosciences Inc (JUNS) amid partnerships with oncology centers combating respiratory pathologies. Research into brain inflammation mechanisms conducted with academics and the development of a resveratrol platform for the therapy of neurological diseases define the strategic vector. This metric is recorded at 0.00, which helps track the business's debt load in real time.

Jupiter Neurosciences (JUNS) - Debts to Book Value from 12/04/2024 to 10/27/2026
Product sample of Jupiter Neurosciences

Assessing the reliability of equity assets begins with an analysis of capital structure stability. This ratio compares total liabilities to the book value of equity, determining the degree of financial leverage. For Jupiter Neurosciences Inc (JUNS), the costs associated with laboratory greening and "green chemistry" require balanced financing. An optimal level of borrowing maintains profitability while adhering to ESG standards. The company's current debt-to-book capitalization ratio objectively reflects this balance.

Competitors of Jupiter Neurosciences Inc (JUNS)

Debt to Book Value BIIB (Biogen Inc.)|neurocrine.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Regencell Bioscience Holdings Limited (RGC)|AXSM: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio ACAD|XENE (Xenon Corp) - Debts to Book Value|Viking Therapeutics (VKTX) - Debt to Book Capitalization Ratio|Debt to Book Capital supernus.com (SUPN)|Debt to Book Value CPRX|Debts to Book Capitalization DNLI (Denali)|Harmony Pharma (HRMY) - Debt to Book Capitalization Ratio|Debts to Book Capitalization Ratio Biohaven Corp BHVN|Debts to Book Capitalization AMLX (Amylyx Pharmaceuticals)|trevitherapeutics.com (TRVI) - Debts to Net Assets|PRAX - Debt to Book Value|Anavex (AVXL) - Debt to Book Capital|Debts to Book Capitalization CBLL (CeriBell Corp)|Debts to Book Value PRTA|Alector, Inc. (ALEC) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio annexonbio.com ANNX|Debt to Book Value Omeros|Neurogene Inc - Debt to Net Assets Ratio|AC Immune Corp (ACIU) - Debt to Book Capitalization Ratio|VYGR - Debt to Book Value Ratio|Debts to Book Capitalization NMRA|Debts to Book Value scilexholding.com|TVGN (Tevogen Bio) - Debt to Book Value|Debts to Book Capitalization ACOG|Cognition Therapeutics (CGTX) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio IKT (Inhibikase Pharma)|SAVA: Debt to Book Capitalization Ratio|Assertio Holdings - Debts to Book Value|Debt to Book Capitalization Ratio COYA (Coya)|VTGN - Debts to Net Assets|OVID (ovidrx.com) - Debts to Book Capitalization|Acumen Pharmaceuticals, Inc (ABOS) - Debt to Book Value|CRVO: Debts to Book Capitalization|Debts to Net Assets Alterity Therapeutics Ltd|Clene Inc. - Debts to Book Capitalization|Debts to Book Value PEPG (pepgen.com)|RLMD - Debt to Book Capitalization Ratio|Debt to Book Value Ratio Annovis Bio Corporation ANVS|GRCE: Debts to Book Capitalization|AIFF - Debt to Book Value|Debts to Book Capitalization KLTO|NRSN (NeuroSense Therapeutics Ltd.) - Debts to Book Value|RVPH: Debt to Book Capitalization Ratio|Debts to Net Assets MetaVia, Inc. (MTVA)|NeurAxis, Inc. (NRXS) - Debt to Book Value|Debt to Net Assets Ratio heliusmedical.com (HSDT)|Debts to Book Capitalization PASG|Neuphoria Therapeutics, Inc. - Debts to Net Assets|Minerva Neurosciences Corp (NERV) - Debt to Book Capitalization Ratio|ATHA - Debt to Book Value Ratio|ADXN (Addex Therapeutics) - Debts to Book Capitalization|ALZN (Alzamend Neuro) - Debt to Book Value|Cyclerion Therapeutics Inc. (CYCN) - Debt to Book Capitalization Ratio|Debt to Book Capital Protagenic (PTIX)|Debt to Book Value KTTA|Debts to Book Capitalization CRGT (cortigent.com)|ATXI - Debt to Book Capitalization Ratio|brainstorm-cell.com - Debt to Book Value Ratio|Debt to Book Capitalization Ratio CARA (Cara Therapeutics)|CHRO: Debts to Net Assets|Debt to Book Capitalization Ratio eliemtx.com|Intra-Cellular Therapies, Inc. (ITCI) - Debt to Book Value Ratio|Debts to Book Capitalization LBPH (Longboard Pharmaceuticals)|Debts to Book Value marinuspharma.com (MRNS)|Debt to Book Value NKGN|Debts to Book Capitalization NRBO (NeuroBo Pharmaceuticals Inc)|Debt to Book Capitalization Ratio Sage Therapeutics, Inc|Synaptogenix, Inc - Debt to Net Assets Ratio|TRVN (Trevena, Inc.) - Debt to Book Capitalization Ratio|VIGL: Debts to Book Value|WENA - Debt to Book Capitalization Ratio|Debt to Book Capital Cerevel Therapeutics Inc